Abstract
Mutations in the RNA binding protein FUS (fused in sarcoma) have been linked to a subset of familial amyotrophic lateral sclerosis (ALS) cases. The mutations are clustered in the C-terminal nuclear localization sequence (NLS). Various FUS mutants accumulate in the cytoplasm whereas wild-type (WT) FUS is mainly nuclear. Here we investigate the effect of one ALS causing mutant (FUS-δNLS, also known as R495X) on pre-mRNA splicing and RNA expression using genome wide exon-junction arrays. Using a non-neuronal stable cell line with inducible FUS expression, we detected early changes in RNA composition. In particular, mutant FUS-δNLS increased calcium/calmodulin-dependent protein kinase II inhibitor 2 (CAMK2N2) at both mRNA and protein levels, whereas WT-FUS had no effect. Chromatin immunoprecipitation experiments showed that FUS-δNLS accumulated at the CAMK2N2 promoter region, whereas promoter occupation by WT-FUS remained constant. Given the loss of FUS-δNLS in the nucleus through the mutation-induced translocation, this increase of promoter occupancy is surprising. It indicates that, despite the obvious cytoplasmic accumulation, FUS-δNLS can act through a nuclear gain of function mechanism.
Original language | English |
---|---|
Pages (from-to) | 1129-1135 |
Number of pages | 7 |
Journal | Biochimica et Biophysica Acta - Molecular Basis of Disease |
Volume | 1832 |
Issue number | 8 |
DOIs | |
State | Published - 2013 |
Bibliographical note
Funding Information:This work is supported by an Endowment from Linda and Jack Gill to the University of Kentucky, funds by Dean Frederick de Beer, National Institutes of Health grant R01NS077284 and the ALS Association grant 6SE340 to H. Z. and NIH RO1 GM083187 and 5P20RR020171-08 to S. S. L. J. H. was supported by the ALS Therapy Alliance.
Keywords
- ALS
- Amyotrophic lateral sclerosis
- Array analysis
- FUS
- Fused in sarcoma
ASJC Scopus subject areas
- Molecular Medicine
- Molecular Biology